Subjective cognitive decline. The first clinical manifestation of Alzheimer’s disease?

Fuente: Redalyc
Saved in:
Bibliographic Details
Main Author: Adalberto Studart Neto
Format: Artículo científico
Language:en
Published: Associação Neurologia Cognitiva e do Comportamento 2016
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1876477278599249920
author Adalberto Studart Neto
author_facet Adalberto Studart Neto
contents Subjective cognitive decline. The first clinical manifestation of Alzheimer’s disease? Adalberto Studart Neto Ricardo Nitrini Medicina dementia biomarkers Alzheimer’s disease Subjective cognitive decline Background: Mild cognitive impairment is considered as the first clinical manifestation of Alzheimer’s disease (AD), when the individual exhibits below performance on standardized neuropsychological tests. However, some subjects before having a lower performance on cognitive assessments already have a subjective memory complaint. Objective: A review about subjective cognitive decline, the association with AD biomarkers and risk of conversion to dementia. Methods: We performed a comprehensive non-systematic review on PubMed. The keywords used in the search were terms related to subjective cognitive decline. Results: Subjective cognitive decline is characterized by self-experience of deterioration in cognitive performance not detected objectively through formal neuropsychological testing. However, various terms and definitions have been used in the literature and the lack of a widely accepted concept hampers comparison of studies. Epidemiological data have shown that individuals with subjective cognitive decline are at increased risk of progression to AD dementia. In addition, there is evidence that this group has a higher prevalence of positive biomarkers for amyloidosis and neurodegeneration. However, Alzheimer’s disease is not the only cause of subjective cognitive decline and various other conditions can be associated with subjective memory complaints, such as psychiatric disorders or normal aging. The features suggestive of a neurodegenerative disorder are: onset of decline within the last five years, age at onset above 60 years, associated concerns about decline and confirmation by an informant. Conclusion: These findings support the idea that subjective cognitive complaints may be an early clinical marker that precedes mild cognitive impairment due to Alzheimer’s disease. 2016 artículo científico 1980-5764 https://www.redalyc.org/articulo.oa?id=339547442002 en http://www.redalyc.org/revista.oa?id=3395 Dementia & Neuropsychologia application/pdf Associação Neurologia Cognitiva e do Comportamento Dementia & Neuropsychologia (Brasil) Num.3 Vol.10
format Artículo científico
id redalyc_339547442002
institution Redalyc
language en
publishDate 2016
publisher Associação Neurologia Cognitiva e do Comportamento
spellingShingle Subjective cognitive decline. The first clinical manifestation of Alzheimer’s disease?
Adalberto Studart Neto
Medicina
dementia
biomarkers
Alzheimer’s disease
Subjective cognitive decline
Subjective cognitive decline. The first clinical manifestation of Alzheimer’s disease? Adalberto Studart Neto Ricardo Nitrini Medicina dementia biomarkers Alzheimer’s disease Subjective cognitive decline Background: Mild cognitive impairment is considered as the first clinical manifestation of Alzheimer’s disease (AD), when the individual exhibits below performance on standardized neuropsychological tests. However, some subjects before having a lower performance on cognitive assessments already have a subjective memory complaint. Objective: A review about subjective cognitive decline, the association with AD biomarkers and risk of conversion to dementia. Methods: We performed a comprehensive non-systematic review on PubMed. The keywords used in the search were terms related to subjective cognitive decline. Results: Subjective cognitive decline is characterized by self-experience of deterioration in cognitive performance not detected objectively through formal neuropsychological testing. However, various terms and definitions have been used in the literature and the lack of a widely accepted concept hampers comparison of studies. Epidemiological data have shown that individuals with subjective cognitive decline are at increased risk of progression to AD dementia. In addition, there is evidence that this group has a higher prevalence of positive biomarkers for amyloidosis and neurodegeneration. However, Alzheimer’s disease is not the only cause of subjective cognitive decline and various other conditions can be associated with subjective memory complaints, such as psychiatric disorders or normal aging. The features suggestive of a neurodegenerative disorder are: onset of decline within the last five years, age at onset above 60 years, associated concerns about decline and confirmation by an informant. Conclusion: These findings support the idea that subjective cognitive complaints may be an early clinical marker that precedes mild cognitive impairment due to Alzheimer’s disease. 2016 artículo científico 1980-5764 https://www.redalyc.org/articulo.oa?id=339547442002 en http://www.redalyc.org/revista.oa?id=3395 Dementia & Neuropsychologia application/pdf Associação Neurologia Cognitiva e do Comportamento Dementia & Neuropsychologia (Brasil) Num.3 Vol.10
title Subjective cognitive decline. The first clinical manifestation of Alzheimer’s disease?
topic Medicina
dementia
biomarkers
Alzheimer’s disease
Subjective cognitive decline
url https://www.redalyc.org/articulo.oa?id=339547442002